So, another Jakafi whiff in cancer. Given the magnitude of the INCY's slide before this one, and the subsequent reaction - currently off 12% - it seems the market is pricing in failure in all solid tumor trials. Most of us here would agree with that take. So does that make INCY a buy here? Two readouts in coming months, lung and breast. The rest fairly late in '17. One trial, to readout in June or so (breast), won't be stopped now, at least.
So many cheap looking biotechs, so little cash, some potential in coming months for even cheaper biotechs. Hmmmm. INCY, or FGEN, or keep waiting. Hmmm.
Cheers, Tuck |
